MOTS-c for Endurance and Performance

What is MOTS-c?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a mitochondrial-derived peptide that, in mice, mimics some effects of exercise. For the compound in general, see our MOTS-c overview, and for every mitochondrial peptide pitched at endurance, see our endurance applications page.

Discovery and Origin

• Described in 2015 by researchers at USC
• Encoded by mitochondrial DNA
• 16 amino acid peptide
• Levels rise during exercise in humans

Mechanism of Action

Primary Pathway: AMPK Activation

In cell and mouse studies, MOTS-c activates AMP-activated protein kinase (AMPK), the cell's energy sensor. AMPK activation:

• Increases fatty acid oxidation
• Enhances glucose uptake
• Promotes mitochondrial biogenesis

None of these effects has been measured in people given MOTS-c.

Exercise Connection

• MOTS-c levels increase with exercise
• May mediate some exercise benefits (a hypothesis, untested in people)

Proposed Benefits for Athletes

Endurance Enhancement

Extrapolated from mouse treadmill data:

• Improved aerobic capacity
• Better exercise tolerance
• Delayed fatigue onset

Metabolic Benefits

In mouse studies, MOTS-c improved insulin sensitivity and limited weight gain on a high-fat diet.

Recovery Support

We found no study that measured recovery after MOTS-c.

Research Evidence

Key Studies

Human Data

• As of October 2026, no published study has given native MOTS-c to people
• The Reynolds human data measured the body's own MOTS-c after exercise; nobody received the peptide
• The analog CB4211 had one liver trial with no exercise endpoints, then was discontinued in 2023

Dosing Protocols

No human trial doses exist for native MOTS-c, so nothing here is a tested protocol.

Reported Protocols (User and Vendor)

• Common user reports: about 10-15 mg per week, often as 5 mg two or three times a week by subcutaneous injection, for 4-8 weeks
• Wider forum range: from about 1 mg three times weekly up to 5-10 mg daily for short blocks
• Analog comparison: CB4211 was given at 25 mg daily in its trial, but it isn't the same molecule

Administration

• Users describe subcutaneous injection
• Users commonly run 4-8 week blocks with breaks; no study has tested cycling

Timing Considerations

Practical Applications

For Endurance Athletes

Users report steadier energy during training and less fatigue, while others notice nothing. With no placebo and unverified vial contents, those reports can't separate a real effect from expectation. As of October 2026, WADA's 2026 Prohibited List names MOTS-c under S4.4.1 (AMPK activators), so it's prohibited at all times for tested athletes (see our page on peptides and sport rules).

For Bodybuilders

Some lifters use it during cutting for fat loss, based on the mouse data.

Stacking Considerations

• No study has tested MOTS-c with other peptides

Safety Profile

Known from Research

• No human safety data exists for native MOTS-c
• In the 4-week CB4211 trial, the company reported no serious adverse events
• Being an endogenous peptide doesn't make injected doses safe

Reported by Users

• Injection-site reactions, often itchy welts or lumps, are the most common complaint
• A few secondhand forum accounts describe allergic-type reactions (unverified)
• Some report fatigue at higher doses

Potential Concerns

• Long-term effects unknown (see our page on long-term health implications)
• Gray-market vial contents and purity are unverified
• As of October 2026, MOTS-c is not approved as a medicine anywhere, and FDA hasn't added it to the 503A compounding list

Monitoring

Users who track their response mention blood glucose and training performance.

Comparison to Other Approaches

Limitations and Considerations

Current Limitations

• No human endurance data
• Doses come from users, not trials
• Availability and quality inconsistent

What we still don't know

• Whether MOTS-c improves endurance in people at any dose
• Whether mouse doses (5-15 mg/kg/day) translate to humans